Pasithea Therapeutics Corp.
KTTA
$0.58
$0.00-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.82% | 91.32% | 23.12% | 4.73% | -14.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.51% | 86.89% | 3.51% | -3.40% | -8.92% |
| Operating Income | -32.51% | -86.89% | -3.51% | 3.40% | 8.92% |
| Income Before Tax | 19.47% | -218.18% | -1.25% | 3.88% | 7.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.47% | -218.18% | -1.25% | 3.88% | 7.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.47% | -218.18% | -1.25% | 3.88% | 7.71% |
| EBIT | -32.51% | -86.89% | -3.51% | 3.40% | 8.92% |
| EBITDA | -34.15% | -91.60% | -3.03% | 3.53% | 9.30% |
| EPS Basic | 92.68% | 68.75% | 85.80% | 82.22% | 56.49% |
| Normalized Basic EPS | 92.68% | 81.62% | 85.80% | 82.22% | 56.49% |
| EPS Diluted | 92.68% | 68.75% | 85.80% | 82.22% | 56.49% |
| Normalized Diluted EPS | 92.68% | 81.62% | 85.80% | 82.22% | 56.49% |
| Average Basic Shares Outstanding | 1,000.66% | 918.07% | 612.92% | 440.72% | 112.11% |
| Average Diluted Shares Outstanding | 1,000.66% | 918.07% | 612.92% | 440.72% | 112.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |